TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival
|
Press Release2026, March 09 08:00 a.m. TME Pharma extends financial runway to over 12 months 2026, January 05 08:00 a.m. TME Pharma provides update on its activities 2025, November 17 08:00 a.m. TME Pharma announces receipt of agreements in principle to extend certain bond agreements |
Latest AricleL-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial
Giordano FA et al. Nature Communications 2026, 17, 3405. Latest Analyst ReportInvest Securities |